

ISSN Print: 2664-8865
ISSN Online: 2664-8873
Impact Factor: RJIF 5.48
IJIR 2023; 5(2): 43-46
www.immunologyjournal.in
Received: 22-06-2023
Accepted: 25-07-2023

Dr. Richard Johnson
Department of Gastroenterology and Immunology, Imperial College London, London, United Kingdom

Corresponding Author:
Dr. Richard Johnson
Department of Gastroenterology and Immunology, Imperial College London, London, United Kingdom

The role of gut microbiota in the pathogenesis of autoimmune diseases

Dr. Richard Johnson

DOI: https://doi.org/10.33545/26648865.2023.v5.i2a.39

Abstract
The gut microbiota, consisting of trillions of microorganisms, plays a critical role in maintaining immune homeostasis and overall health. Emerging evidence suggests that alterations in gut microbiota composition, or dysbiosis, may contribute to the development and progression of autoimmune diseases. This review aims to explore the mechanisms by which gut microbiota influences the pathogenesis of autoimmune diseases, including its role in modulating immune responses, maintaining intestinal barrier integrity, and interacting with genetic and environmental factors. We also discuss current therapeutic strategies targeting the gut microbiota, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), as potential treatments for autoimmune diseases.

Keywords: Gut microbiota, autoimmune diseases, pathogenesis

Introduction
Autoimmune diseases are characterized by the immune system's aberrant response against self-antigens, leading to chronic inflammation and tissue damage. These diseases encompass a wide range of conditions, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and type 1 diabetes, among others. While the exact etiology of autoimmune diseases remains unclear, a combination of genetic predisposition and environmental triggers is thought to be involved. In recent years, the gut microbiota has emerged as a critical environmental factor influencing the onset and progression of autoimmune diseases.
The human gut microbiota is a complex and dynamic community of microorganisms, including bacteria, viruses, fungi, and archaea, that reside in the gastrointestinal tract. This microbiota plays a fundamental role in various physiological processes, such as digestion, metabolism, and immune regulation. The balance between the gut microbiota and the host immune system is essential for maintaining health. However, disruptions in this balance, or dysbiosis, have been linked to the development of various autoimmune diseases.

Objective of the paper
The objective of this paper is to explore the mechanisms by which gut microbiota modulates the immune system and its role in the pathogenesis of autoimmune diseases.

Gut Microbiota and Immune System Modulation
The gut microbiota plays a pivotal role in the development and function of the host immune system, influencing both local gut immunity and systemic immune responses. The intricate relationship between the gut microbiota and the immune system is crucial for maintaining immune homeostasis and preventing excessive inflammation or autoimmunity. Dysregulation of this relationship, often due to an imbalance in the composition or function of the gut microbiota (dysbiosis), can lead to the development and progression of autoimmune diseases. This section delves into the mechanisms by which the gut microbiota modulates the immune system, supported by relevant studies.

Development and Maturation of the Immune System
The colonization of the gut by microbiota begins at birth and plays a critical role in the maturation of the immune system. Germ-free (GF) animal studies, where animals are raised

in sterile environments without exposure to any microorganisms, have provided significant insights into the influence of gut microbiota on immune development. These studies have shown that GF animals exhibit underdeveloped immune systems, with fewer and less active immune cells, including T cells, B cells, and antigen-presenting cells, as well as lower levels of immunoglobulins. When GF animals are colonized with normal gut microbiota, their immune systems mature, highlighting the essential role of microbiota in immune development.

A study by Round and Mazmanian (2010) demonstrated that specific gut bacteria, such as *Bacteroides fragilis*, can modulate immune responses through the production of polysaccharide A (PSA), a microbial molecule that promotes the differentiation of regulatory T cells (Tregs). Tregs are critical for maintaining immune tolerance to self-antigens and preventing autoimmune reactions. In the absence of *B. fragilis* or PSA, the immune system is skewed towards pro-inflammatory responses, increasing the risk of autoimmune diseases. This study underscores the role of specific gut bacteria in shaping the immune system and preventing autoimmunity.

Regulation of T cell responses

The gut microbiota significantly influences the balance between different T cell subsets, particularly Tregs and T helper 17 (Th17) cells. Tregs are essential for maintaining immune tolerance, while Th17 cells are involved in defending against extracellular pathogens but are also implicated in promoting inflammation and autoimmunity when dysregulated.

Studies have shown that certain commensal bacteria promote the expansion and function of Tregs. For instance, *Clostridia* species, particularly clusters IV and XIVa, have been identified as potent inducers of Tregs in the colon. Atarashi *et al*. (2013) demonstrated that colonization of GF mice with a mix of 17 strains of *Clostridia* led to a significant increase in colonic Treg numbers, accompanied by enhanced production of anti-inflammatory cytokines such as IL-10. The presence of these bacteria was associated with reduced susceptibility to colitis and systemic autoimmunity, indicating their protective role in immune regulation.

Conversely, certain gut bacteria are associated with the promotion of Th17 cell differentiation, which can exacerbate autoimmune conditions. *Segmented filamentous bacteria* (SFB) have been shown to induce Th17 cells in the gut, leading to increased production of pro-inflammatory cytokines such as IL-17. Gaboriau-Routhiau *et al*. (2009) found that SFB colonization in mice led to the expansion of Th17 cells, which contributed to the development of autoimmune arthritis in genetically susceptible models. This finding illustrates how specific microbial species can influence immune pathways that drive autoimmunity.

Production of Short-Chain Fatty Acids (SCFAs)

The gut microbiota contributes to the production of short-chain fatty acids (SCFAs) through the fermentation of dietary fibers. SCFAs, particularly butyrate, propionate, and acetate, play a crucial role in maintaining intestinal health and modulating immune responses. SCFAs serve as energy sources for colonocytes, help maintain the integrity of the intestinal barrier, and have anti-inflammatory effects on the immune system.

Butyrate, in particular, has been shown to enhance the function of Tregs and suppress the activity of pro-inflammatory immune cells. Furusawa *et al*. (2013) demonstrated that butyrate promotes the differentiation of Tregs by increasing the expression of the transcription factor Foxp3, which is essential for Treg function. Moreover, butyrate inhibits the production of pro-inflammatory cytokines by macrophages and dendritic cells, thus reducing inflammation.

SCFAs also influence the expression of G protein-coupled receptors (GPRs), such as GPR43 and GPR109A, on immune cells. These receptors mediate the anti-inflammatory effects of SCFAs, including the inhibition of nuclear factor kappa B (NF-κB) signaling, a pathway that drives inflammation. The activation of SCFA receptors on immune cells has been associated with reduced inflammation and protection against autoimmune diseases in animal models.

Impact on mucosal immunity

The gut microbiota plays a central role in the regulation of mucosal immunity, which is the first line of defense against pathogens in the gastrointestinal tract. The gut-associated lymphoid tissue (GALT), which includes Peyer's patches, isolated lymphoid follicles, and mesenteric lymph nodes, is a key site for the interaction between the microbiota and the immune system.

Commensal bacteria help maintain the balance of mucosal immunity by promoting the production of secretory IgA (sIgA), a crucial antibody that binds to pathogens and prevents their translocation across the intestinal epithelium. sIgA also facilitates the clearance of antigens and modulates immune responses, promoting tolerance to non-pathogenic antigens while defending against harmful microbes. Studies have shown that GF animals have significantly reduced levels of sIgA, leading to increased susceptibility to infections and inflammatory diseases.

Additionally, the gut microbiota influences the production of antimicrobial peptides, such as defensins and cathelicidins, by intestinal epithelial cells. These peptides provide a chemical barrier that limits microbial invasion and shapes the composition of the gut microbiota. Dysbiosis, characterized by a reduction in beneficial bacteria and an overgrowth of pathobionts, can disrupt this balance and lead to chronic inflammation and autoimmunity.

Interaction with Systemic Immunity

The influence of the gut microbiota extends beyond the gut, affecting systemic immunity through the migration of immune cells and the circulation of microbial metabolites. For example, microbial metabolites, such as SCFAs, can enter the bloodstream and modulate the function of immune cells in distant organs. Butyrate, for instance, has been shown to inhibit the activation of dendritic cells and macrophages in peripheral tissues, reducing systemic inflammation.

Moreover, the gut microbiota can influence the migration of immune cells from the gut to other tissues, where they can contribute to immune surveillance or pathological inflammation. For instance, gut-derived Tregs can migrate to the central nervous system (CNS) and play a role in modulating neuroinflammation, which is relevant in the context of autoimmune diseases like multiple sclerosis.

The gut microbiota also interacts with other components of the immune system, such as the complement system and innate lymphoid cells (ILCs), further modulating immune responses. Dysbiosis has been linked to the dysregulation of these immune pathways, contributing to the development of systemic autoimmune diseases.

Intestinal Barrier Integrity and Autoimmunity

The intestinal barrier is a crucial component of the gut that separates the gut microbiota from the underlying immune cells and systemic circulation. It consists of a single layer of epithelial cells connected by tight junctions, along with mucus and antimicrobial peptides. This barrier is essential for preventing the translocation of harmful microbes and antigens into the bloodstream, where they can trigger immune responses.

Dysbiosis can compromise intestinal barrier integrity, leading to increased intestinal permeability, commonly referred to as "leaky gut." When the intestinal barrier is breached, microbial products such as lipopolysaccharides (LPS) and other antigens can enter the circulation and trigger systemic immune responses. These responses can contribute to the development of autoimmune diseases by promoting chronic inflammation and the activation of autoreactive immune cells.

Several autoimmune diseases, including celiac disease, type 1 diabetes, and inflammatory bowel disease (IBD), have been associated with increased intestinal permeability. For instance, in type 1 diabetes, studies have shown that increased intestinal permeability precedes the onset of the disease, suggesting that a leaky gut may be an early event in the pathogenesis of autoimmune diabetes. Moreover, restoring intestinal barrier function through dietary interventions, probiotics, or other therapies has been shown to reduce disease severity in animal models of autoimmunity.

Interaction with Genetic and Environmental Factors

The development of autoimmune diseases is influenced by a complex interplay between genetic predisposition and environmental factors. The gut microbiota is a key environmental factor that can interact with the host's genetic makeup to influence disease risk. For example, specific gut bacteria can modulate the expression of genes involved in immune regulation, potentially triggering autoimmune responses in genetically susceptible individuals.

The gut microbiota can also interact with environmental factors such as diet, infections, and medications, which are known to influence the risk of autoimmune diseases. Dietary components, particularly those that affect gut microbiota composition, such as fiber, fat, and processed foods, can either promote or protect against autoimmunity. For instance, high-fiber diets that promote the growth of SCFA-producing bacteria have been shown to reduce the risk of autoimmune diseases, while diets high in saturated fats and processed foods have been associated with increased disease risk.

Infections can also alter gut microbiota composition and contribute to the onset of autoimmune diseases. Molecular mimicry, where microbial antigens resemble self-antigens, can lead to cross-reactive immune responses that trigger autoimmunity. Additionally, the use of antibiotics and other medications that disrupt gut microbiota balance can increase the risk of autoimmune diseases by reducing microbial diversity and promoting dysbiosis.

Therapeutic Strategies Targeting the Gut Microbiota

Given the emerging evidence linking gut microbiota to autoimmune diseases, several therapeutic strategies are being explored to modulate the microbiota and restore immune balance. Probiotics, which are live microorganisms that confer health benefits to the host, have shown promise in improving gut microbiota composition and reducing autoimmune disease severity. Specific strains of probiotics, such as *Lactobacillus* and *Bifidobacterium*, have been studied for their ability to enhance Treg function and reduce inflammation.

Prebiotics, which are non-digestible fibers that promote the growth of beneficial gut bacteria, are also being investigated as a therapeutic approach. By increasing the production of SCFAs, prebiotics can help restore intestinal barrier integrity and modulate immune responses. Additionally, fecal microbiota transplantation (FMT), which involves the transfer of stool from a healthy donor to a patient, has been explored as a treatment for autoimmune diseases. FMT has shown success in treating conditions like recurrent Clostridium difficile infection and is now being studied for its potential in autoimmune diseases.

Despite the promising potential of these therapies, challenges remain in translating them into clinical practice. The complexity and variability of the gut microbiota among individuals make it difficult to develop one-size-fits-all treatments. Additionally, long-term studies are needed to assess the safety and efficacy of these therapies in autoimmune diseases.

Conclusion

The gut microbiota plays a central role in the pathogenesis of autoimmune diseases by modulating immune responses, maintaining intestinal barrier integrity, and interacting with genetic and environmental factors. Dysbiosis, or an imbalance in the gut microbiota, can contribute to the onset and progression of autoimmunity. Therapeutic strategies targeting the gut microbiota, such as probiotics, prebiotics, and FMT, hold promise for the treatment of autoimmune diseases. However, further research is needed to fully understand the complex interactions between the gut microbiota and the immune system and to develop effective microbiota-based therapies for autoimmune conditions.

Conflict of Interest

Not available

Financial Support

Not available

References

1. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2010;10(11):736–44. DOI: 10.1038/nri2850.
2. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, *et al*. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2013;331(6015):337–41. DOI: 10.1126/science.1198469.

3. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, Mulder I, Lan A, Bridonneau C, *et al*. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31(4):677–89. DOI: 10.1016/j.immuni.2009.08.020.
4. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, *et al*. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–50. DOI: 10.1038/nature12721.
5. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535(7610):75–84. DOI: 10.1038/nature18848.
6. Jarchum I, Pamer EG. Regulation of innate and adaptive immunity by the commensal microbiota. Curr Opin Immunol. 2011;23(3):353–60. DOI: 10.1016/j.coi.2011.03.001.
7. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, *et al*. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. DOI: 10.1038/nature11450.
8. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol. 2008;24(1):4–10. DOI: 10.1097/MOG.0b013e3282f2b0ad.
9. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48. DOI: 10.1016/j.cell.2006.02.017.
10. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121(6):2126–32. DOI: 10.1172/JCI58109.
11. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, *et al*. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262–7. DOI: 10.1126/science.1223813.
12. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–73. DOI: 10.1126/science.1223490.
13. Arumugam M, Raes J, Pelletier E, Paslier DL, Yamada T, Mende DR, *et al*. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–80. DOI: 10.1038/nature09944.

How to Cite This Article
Johnson R. The role of gut microbiota in the pathogenesis of autoimmune diseases. International Journal of Immunology Research 2023; 5(2): 43-46.